Mednax (MD) Q4 Revenue, Earnings Beat Estimates

Mednax (MD) reported quarterly earnings of $0.91 per share, beating the Zacks Consensus Estimate of $0.90 per share. That compares with earnings of $0.92 per share a year ago. These figures are adjusted for one-time items.

This quarterly report represents an earnings surprise of 1.11%. A quarter ago, the physician group was expected to post earnings of $0.91 per share when the actual earnings were $0.91, which was no surprise at all.

The company has topped consensus earnings per share estimates twice over the last four quarters.

Mednax, which belongs to the Zacks Medical – Hospital industry, posted revenues of $905.38 million for the quarter ended December 2019, surpassing the Zacks Consensus Estimate by 0.50%. This compares to year-ago revenues of $932.70 million. The company has topped the consensus revenue estimate three times over the last four quarters.

The sustainability of current share price movements based on recently released data and future earnings expectations will depend primarily on management’s commentary following the earnings conference call.

Mednax shares have lost about 4.3% since the beginning of the year, while the S&P 500 has gained 4.8%.

What’s next for Mednax?

Even though Mednax has underperformed the market this year, investors are wondering: What’s next for the stock?

There are no easy answers to this key question, but one reliable indicator that can help investors address this is the company’s earnings outlook. This includes not only the current consensus earnings expectations for the coming quarter(s), but also how those expectations have changed recently.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings report, the estimate revision trend for Mednax was unfavorable. While the magnitude and direction of estimate revisions could change following the company’s just-released earnings report, the current status translates into a Zacks Rank #5 (Strong Sell) for the stock. Thus, the stock is expected to underperform the market in the near future. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the upcoming quarters and current fiscal year change in the coming days. The current consensus EPS estimate is $0.66 on $875.05 million in revenue for the coming quarter and $3.38 on $3.59 billion in revenue for the current fiscal year.

Investors should be aware that the outlook for the industry can also have a significant impact on stock performance. In terms of the Zacks Industry Rank, Medical – Hospital currently ranks in the top 31% of the 250+ Zacks industries. Our research shows that the top 50% of Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Want the latest recommendations from Zacks Investment Research? Today you can download the 7 best stocks for the next 30 days. Click to get this free report

To read this article on Zacks.com click here.

Zacks Investment Research